FDA Drug Recalls
557 recalls, newest first
Class II · Moderate risk Terminated Nov 14, 2024
Reason CGMP deviations: the bulk product was rejected by the Quality Unit after routine inspection of the mixing vessel showed scratches on the sides and…
Class II · Moderate risk Terminated Nov 14, 2024
Reason CGMP Deviations: Released product should have been rejected.
Class III · Low risk Ongoing Nov 14, 2024
Reason Labeling: Not Elsewhere Classified - Wrong NDC number
Class II · Moderate risk Ongoing Nov 14, 2024
Reason CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit
Class II · Moderate risk Ongoing Nov 14, 2024
Reason CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit
Class II · Moderate risk Ongoing Nov 14, 2024
Reason CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit
Class II · Moderate risk Ongoing Nov 13, 2024
Reason CGMP Deviations: lack of adequate release testing.
Class II · Moderate risk Ongoing Nov 11, 2024
Reason Presence of Particulate Matter: Potential for glass delamination from the vials.
Class II · Moderate risk Ongoing Nov 11, 2024
Reason Presence of Particulate Matter: Potential for glass delamination from the vials.
Class II · Moderate risk Ongoing Nov 11, 2024
Reason Presence of Particulate Matter: Potential for glass delamination from the vials.
Class II · Moderate risk Ongoing Nov 11, 2024
Reason cGMP Deviations: Observations were made that some blister card-foils were separating from the blister cavity.
Class II · Moderate risk Ongoing Nov 11, 2024
Reason cGMP Deviations: Observations were made that some blister card-foils were separating from the blister cavity.
Class II · Moderate risk Ongoing Nov 11, 2024
Reason cGMP Deviations: Observations were made that some blister card-foils were separating from the blister cavity.
Class II · Moderate risk Ongoing Nov 11, 2024
Reason cGMP Deviations: Observations were made that some blister card-foils were separating from the blister cavity.
Class II · Moderate risk Ongoing Nov 11, 2024
Reason cGMP Deviations: Observations were made that some blister card-foils were separating from the blister cavity.
Class II · Moderate risk Ongoing Nov 8, 2024
Reason Subpotent drug
Class II · Moderate risk Ongoing Nov 7, 2024
Reason cGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit
Class II · Moderate risk Ongoing Nov 7, 2024
Reason cGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit
Class II · Moderate risk Ongoing Nov 7, 2024
Reason cGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit
Class II · Moderate risk Terminated Nov 7, 2024
Reason Failed Impurity/Degradation Specifications
Class II · Moderate risk Terminated Nov 7, 2024
Reason Failed Impurity/Degradation Specifications
Class II · Moderate risk Ongoing Nov 6, 2024
Reason cGMP Deviations: Out of specification results for micro in hand soap products.
Class II · Moderate risk Ongoing Nov 6, 2024
Reason cGMP Deviations: Out of specification results for micro in hand soap products.
Class II · Moderate risk Ongoing Nov 6, 2024
Reason cGMP Deviations: Out of specification results for micro in hand soap products.
Class II · Moderate risk Ongoing Nov 6, 2024
Reason cGMP Deviations: Out of specification results for micro in hand soap products.